HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Direct Seller's CBD Supplement Recall Mandated, More Ranitidine, Tween Cosmetic Recalls

Executive Summary

FDA's latest recalls records update includes Basic Reset CBD supplements and another 4,300 units of Tween Brands cosmetics containing colors made from banned dye. Recalls resulting from testing of ranitidine drugs reported by Dr. Reddy's.

You may also be interested in...



One-offs Lift Dr Reddy’s In Q2, Eyes Gx Suboxone Opportunities

One-offs aided Dr Reddy’s performance in the second quarter although US growth was flat amid challenges including the recall of ranitidine. But the Indian firm is enthused about fresh potential opportunities for generic Suboxone in the US in view of Indivior’s intent to discontinue its authorized generic.

OTC Heartburn Remedy Options Remain Robust Without Ranitidine

FDA advising consumers to choose other heartburn OTCs but isn't ordering ranitidine off market. Consumers concerned about Johnson's Baby Powder due to potential asbestos can choose not only from other brands, but also from Johnson's in containers other than 22-ounce option on recall.

Aurolife OTC Fexofenadine, Tween Brands Just Shine Cosmetics Among Recalls

Consumer health and cosmetic product recalls added to FDA database on 18 and 25 September also include lidocaine topicals Ridge Properties provides for use in OTC products marketed as pre-tattoo prep or for pain or itch relief after the products were found to be contaminated and above specification for lidocaine assay.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel